Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC

Pan, C; Duan, HJ; Wu, YN; Zhu, CP; Yi, CH; Duan, Y; Lu, DM; Guo, C; Wu, DQ; Wang, YY; Fu, XH; Xu, J; Chen, YD; Luo, M; Tian, W; Pan, T; Xu, WH; Zhang, SZ; Huang, JJ

Zhang, SZ (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst,Natl Minist Educ,Key Lab Canc Prevent &, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.; Huang, JJ (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.

INTERNATIONAL JOURNAL OF ONCOLOGY, 2020; 57 (4): 939

Abstract

Lung cancer has the highest incidence and mortality rates among the malignant tumor types world-wide. Platinum-based chemotherapy is the main treatmen......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索